Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1354-1360
Published online before print April 5, 2007, doi: 10.1161/ATVBAHA.107.140913
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
27/6/1354    most recent
ATVBAHA.107.140913v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodriguez-Feo, J. A.
Right arrow Articles by Pasterkamp, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez-Feo, J. A.
Right arrow Articles by Pasterkamp, G.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:1354.)
© 2007 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Low Levels of Nogo-B in Human Carotid Atherosclerotic Plaques Are Associated With an Atheromatous Phenotype, Restenosis, and Stenosis Severity

Juan A. Rodriguez-Feo; Willem E. Hellings; Bart A.N. Verhoeven; Frans L. Moll; Dominique P.V. de Kleijn; Jay Prendergast; Yuan Gao; Yolanda van der Graaf; George Tellides; William C. Sessa; Gerard Pasterkamp

From the Department of Cardiology, Experimental Cardiology Laboratory (J.A.R.-F., W.E.H., B.A.N.V., D.P.V.d.K., G.P.), University Medical Center, Utrecht, the Netherlands; the Interuniversity Cardiology Institute of the Netherlands (ICIN) (D.P.V.d.K., G.P.), Utrecht, the Netherlands; the Department of Vascular Surgery (W.E.H., B.A.N.V., F.L.M.), University Medical Center, Utrecht, the Netherlands; the Department of Pharmacology (J.P., Y.G., W.C.S.), Boyer Center for Molecular Medicine, Yale University School of Medicine, New Haven, Conn; the Julius Center for Health Sciences and Primary Care (Y.v.d.G.), Utrecht, The Netherlands; and the Department of Surgery (G.T.), Yale University School of Medicine, New Haven, Conn.

Correspondence to Gerard Pasterkamp, MD, PhD, Department of Cardiology, Experimental Cardiology Laboratory, University Medical Center, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands. E-mail gpasterk{at}umcutrecht.nl

Objective— Reticulon-4/Nogo (Nogo-B) protects mouse arteries from lumen loss by reducing smooth muscle cell (SMC) migration and intimal thickening. Our goal was to determine plaque and circulating levels of Nogo-B in atherosclerotic and control subjects. Therefore, we studied the relationships between local Nogo-B, plaque characteristics, and clinical data in patients undergoing carotid endarterectomy.

Methods and Results— Western blot analysis showed that endarterectomy specimens from the femoral (n=19) and carotid arteries (n=145) contained significantly less Nogo-B than nonatherosclerotic mammary arteries (n=8; P<0.003) and aortas (n=15; P=0.03). Immunohistochemistry revealed that in atherosclerotic lesions, Nogo-B was expressed by macrophage/foam cells, SMC rich, and neo-vascularized areas. Atheromatous plaques (>40% fat content) showed a significant reduction in Nogo-B expression (P=0.002). Nogo-B expression levels were significantly lower in patients with more than 90% of carotid stenosis (P=0.04) or restenotic lesions after prior carotid intervention (duplex; P=0.01). In contrast, plasmatic levels of Nogo-B (soluble Nogo-B) did not differ between atherosclerotic subjects (n=68) and risk-factor matched controls (n=63; P=0.5).

Conclusion— Our findings suggest that local reduction of Nogo-B in atherosclerotic tissue might contribute to plaque formation and/or instability triggering luminal narrowing. In contrast, plasma Nogo-B levels are not associated with clinically manifested atherosclerotic disease.

Nogo B protects arteries from lumen loss by reducing smooth muscle cell migration and intimal thickening. We report that low levels of Nogo B are associated with atheromatous plaques and stenotic lesions. Therefore, reduction of Nogo B in atherosclerotic tissue might contribute to plaque formation and/or instability triggering luminal narrowing.


Key Words: atherosclerosis • restenosis • vascular biology • Nogo-B




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Yu, C. Fernandez-Hernando, Y. Suarez, M. Schleicher, Z. Hao, P. L. Wright, A. DiLorenzo, T. R. Kyriakides, and W. C. Sessa
Reticulon 4B (Nogo-B) is necessary for macrophage infiltration and tissue repair
PNAS, October 13, 2009; 106(41): 17511 - 17516.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
P. T.G. Bot, I. E. Hoefer, J. P.G. Sluijter, P. van Vliet, A. M. Smits, F. Lebrin, F. Moll, J.-P. de Vries, P. Doevendans, J. J. Piek, et al.
Increased Expression of the Transforming Growth Factor-{beta} Signaling Pathway, Endoglin, and Early Growth Response-1 in Stable Plaques
Stroke, February 1, 2009; 40(2): 439 - 447.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
T. A. Bullard, T. L. Protack, F. Aguilar, S. Bagwe, H. T. Massey, and B. C. Blaxall
Identification of Nogo as a novel indicator of heart failure
Physiol Genomics, January 17, 2008; 32(2): 182 - 189.
[Abstract] [Full Text] [PDF]